Fig. 3

Influence of baseline proinflammatory markers on overall survival (OS) of patients who were readministered with tyrosine kinase inhibitors (a) OS between patients with high and low baseline neutrophil-to-lymphocyte ratio (NLR); (b) OS between patients with high and low lymphocyte-to-monocyte ratio (LMR)